Ascorbic acid: a promising agent in chronic kidney disease?

Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an impo...

Descripción completa

Detalles Bibliográficos
Autores principales: Karahan, Salih, Afsar, Baris, Kanbay, Mehmet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Cardiovascular Disease in CKD
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6070088/
https://www.ncbi.nlm.nih.gov/pubmed/30094017
http://dx.doi.org/10.1093/ckj/sfy044
Descripción
Sumario:Asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, is related with impaired endothelial function and poor outcomes in chronic kidney disease (CKD) patients. In addition, oxidative stress and inflammation are also a common problem in CKD patients, and both have an important role in the development and progression of atherosclerosis and increased cardiovascular events in CKD. Ascorbic acid might be a promising agent in CKD for improving outcome by decreasing oxidative stress and ADMA levels.

Ejemplares similares